AZ ($AZN), BMS combo pill targets bigger diabetes share

With diabetes on the rise not only in wealthy, overweight nations like the U.S., but in developing countries as well, new treatments are expected to be important for drugmakers looking to beef up their sales. But what do you do when your new diabetes drug doesn't take the market by storm? Combine it with another drug, of course.

Such is the story of Onglyza, the Bristol-Myers Squibb ($BMS)/AstraZeneca ($AZN) diabetes treatment launched last summer. By the third quarter of this year, Onglyza sales only contributed $47 million to BMS's revenues. But now, the companies have won approval of Kombiglyze, a once-a-day combo pill incorporating Onglyza and the commonly used diabetes drug metformin XR.

So, this is how BMS and AZ aim to capture a bigger share of the diabetes market. A recent Decision Resources report showed that Onglyza was already wooing patients away from its direct rival Januvia, made by Merck. And the Januvia-metformin combo drug--Janumet--is a twice-daily pill. Fewer doses mean more convenience, which can translate into bigger sales.

- get the news from Bloomberg
- see the Forbes story
- read the article from Reuters

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.